share_log

Piper Sandler Downgrades Eagle Pharmaceuticals to Underweight, Lowers Price Target to $17

Piper Sandler Downgrades Eagle Pharmaceuticals to Underweight, Lowers Price Target to $17

派珀·桑德勒將Eagle Pharmicals的評級下調至減持,將目標股價下調至17美元
Benzinga ·  2023/08/09 12:12

Piper Sandler analyst David Amsellem downgrades Eagle Pharmaceuticals (NASDAQ:EGRX) from Neutral to Underweight and lowers the price target from $26 to $17.

Piper Sandler分析師David·安塞萊姆將鷹牌製藥(納斯達克:EGRX)評級從中性下調至減持,並將目標價從26美元下調至17美元。

声明:本內容僅用作提供資訊及教育之目的,不構成對任何特定投資或投資策略的推薦或認可。 更多信息
    搶先評論